Skip directly to site content Skip directly to page options Skip directly to A-Z link


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
														Search
		×
			NIOSH
			NIOSH
				All CDC
				Submit
			For a full list of topics:A-Z Index
			Advanced Search
		Advanced Search


The National Institute for Occupational Safety and Health (NIOSH)


Facebook
        Twitter
        LinkedIn
        Syndicate





CYCLOHEXANONE								Related Pages
										*OSHA comments from the January 19, 1989 Final Rule on Air Contaminants Project extracted from 54FR2332 et. seq. This rule was remanded by the U.S. Circuit Court of Appeals and the limits are not currently in force.*
**CAS:** 108-94-1; **Chemical Formula:** C6H10O
OSHA’s former limit for cyclohexanone was 50 ppm as an 8-hour TWA. The Agency proposed to reduce this limit to 25 ppm and to add a skin notation for this substance. NIOSH (Ex. 8-47, Table N1) concurred with this proposed limit. The final rule establishes an 8-hour TWA PEL of 25 ppm and includes a skin notation. Both the ACGIH and NIOSH recommend a time-weighted average for cyclohexanone of 25 ppm, and the ACGIH also recommends a skin notation. Cyclohexanone is a white to pale yellow, oily liquid with an odor similar to that of acetone and peppermint.
Cyclohexanone has been studied in several experimental animal species. A concentration of 2000 ppm inhaled for four hours was lethal to one of six rats; at 4000 ppm, all of the exposed animals died. In rabbits, the dermal LD(50) was 1000 mg/kg (Smyth, Carpenter, Weil et al. 1969/Ex. 1-442). Rabbits showed marked irritation and some corneal injury when undiluted cyclohexanone was instilled in the eye (Carpenter and Smyth 1946/Ex. 1-859). Guinea pigs exposed to 4000 ppm for six hours showed narcotic symptoms, lacrimation, salivation, depression of body temperature and heart rate, and corneal opacity (Specht, Miller, Valaer, and Sayers 1940/Ex. 1-1179). Rabbits exhibited degenerative changes of the liver and kidneys after 50 daily six-hour inhalation exposures to 190 ppm (Treon, Crutchfield, and Kitzmiller 1943b/Ex. 1-394). Exposures to 309 ppm cyclohexanone on the same regimen caused conjunctival congestion, while exposures to 3000 ppm were lethal to some of the exposed animals (Treon, Crutchfield, and Kitzmiller 1943b/Ex. 1-394).
In humans, Nelson and co-workers (1943/Ex. 1-66) reported that irritation caused by exposure to cyclohexanone was intolerable at 50 ppm; however, 25 ppm was not objectionable to most subjects in three- to five-minute exposures (Nelson, Enge, Ross et al. 1943/Ex. 1-66).
OSHA is adding a skin notation for cyclohexanone based on this substance’s ability to cause systemic toxicity through dermal absorption. L.H. Hecker, Director of Corporate Industrial Hygiene and Toxicology at Abbott Laboratories, comment that, in his opinion, there was no evidence for cyclohexanone’s dermal toxicity, and thus that no skin notation was necessary (Ex. 3-678). However, OSHA has determined, based on a review of the evidence for this substance, that cyclohexanone has a dermal LD(50) of 1000 mg/kg in rabbits ( Dangerous Properties of Industrial Materials, 7th ed., p. 997, Sax and Lewis 1989). The Agency believes it appropriate to establish a skin notation for substances posing a percutaneous hazard, which OSHA is defining as any substance having a dermal LD(50) in rabbits of 1000 mg/kg or less. Accordingly, the Agency is including a skin notation for cyclohexanone in the final rule (see Section VI.C.18 for a full discussion of the Agency’s policy on skin notations).
In the final rule, OSHA is establishing an 8-hour TWA for cyclohexanone of 25 ppm, with a skin notation. The Agency has determined that these limits will protect workers from the significant risks of liver and kidney damage, skin and respiratory-tract irritation, and percutaneous absorption associated with exposure to this substance. OSHA finds that skin and respiratory-tract irritation and liver and kidney damage all constitute material health impairments.
										
							
								Page last reviewed:  September 28, 2011						Content source:  	National Institute for Occupational Safety and Health NIOSH
1988 OSHA PEL Project Documentation
Index of Chemical Names
Index of CAS Numbers Follow NIOSH Facebook
Pinterest
Twitter
YouTube
 NIOSH Homepage NIOSH A-Z
Workplace Safety & Health Topics
Publications and Products
Programs
Contact NIOSH


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue